Approval for Gleevec in record time, Brian Druker
Interviewee: Brian Druker. Brian Druker credits the drug company Novartis with recognizing the importance of Gleevec and accelerating the development and approval process. (DNAi Location: Applications > Genes and medicine > Drug design > Brian Druker > Approval in record time)
And fortunately those phase 1 clinical trials were remarkably successful and then there was no looking back. Now Novartis at that point recognizing that they had a remarkably successful drug put resources behind this development like you couldn't imagine and accelerated the development of this drug through phase 2 and phase 3 and to market approval in record time. And so all the time that was lost while they were trying to make decisions about developing was caught up on the other end and they really deserve a huge amount of credit for once they realized they had something so successful for putting the major resources into its development that got it to patients as quickly as it did.
chronic myeloid leukemia,phase 1 clinical trials,brian druker,gleevec,time brian,location applications,market approval,major resources,dnai,record time,interviewee,cml,phase 3,novartis,phase 2,leukemia,genes,decisions,medicine
- ID: 15056
- Source: DNALC.DNAi
- Download: Theora Video MPEG 4 Video
15042. The first day of clinical trials for Gleevec, Bud and Yvonne
Yvonne, Bud's wife, talks about the first day of the clinical trials in June of 1998.
15057. Before and after Gleevec, Brian Druker
Brian Druker talks about the drug he developed as a turning point in the war on cancer.
15054. Restoring hope with Gleevec, Brian Druker
Brian Druker talks about how Gleevec has restored patients' hope for the future.
15082. Shutting down cancer with Gleevec, Brian Druker
Brian Druker reflects on the importance of understanding the causes of cancer for developing new treatments.
15055. Using DNA science to control CML, Brian Druker
Brian Druker talks about how the drug he designed targets the molecular cause of CML.
15041. Getting the diagnosis of chronic myeloid leukemia, Bud
Bud recounts receiving the diagnosis that he had chronic myeloid leukemia.
15058. The first clinical success with Gleevec, Brian Druker
Brian Druker talks about Bud, the first patient restored to health by Gleevecâ¢.
1016. Diagnosis, Targeted therapies: Targeting activators, Sawyer 4
Professor Charles Sawyer explains that EGF receptor happens to be the driver in at least 10% of lung cancer patients in the U.S.
16109. Sense of urgency, Brian Druker
Brian Druker talks about sense of urgency.
1014. Diagnosis, Targeted therapies: Targeting activators, Sawyer 2
Professor Charles Sawyer explains that Gleevec is a pill taken once a day and works remarkably well in all phases of CML.